Objective: Antidepressants (ADs) are the mainstay of treatment for major depressive disorder (MDD). Despite their widespread usage, a consensus does not exist as to the timing of clinically significant symptomatic improvement during an AD trial. The objective of this review is to provide practitioners with empirically based recommendations pertaining to the optimal duration of index (initial) AD therapy before a clinical intervention is warranted.
Abbreviations

Clinical Implications
• AD treatment response outcomes in MDD are heterogeneous, and dependent on symptom severity. Available data suggest subpopulations of people respond early, late, and continuously over time.
• Patient response to index treatment should be monitored and systematically measured (for example, with the Patient Health Questionnaire-9 or the HRSD-7) during each follow-up visit (every other week) for at least the first 8 weeks.
• A lack of improvement (that is, less than 20% decrease from baseline in the HRSD-7 score) after 3 to 4 weeks of treatment would be grounds for a clinical intervention (for example, dosage optimization and [or] augmentation).
Limitations
• Outcomes with available studies are based on grouplevel data rather than on individuals.
• Methodological heterogeneity in sample composition and treatment assignment as well as statistical approaches significantly affect characterization of patient subpopulations.
• Baseline phenomenological and (or) biological predictors of response have yet to be empirically established for the various AD modalities.
C onventional ADs are considered first-line treatment for people with MDD. Despite their widespread availability and increasing usage, a consensus does not exist as to what constitutes an adequate duration for an AD trial before it is deemed inefficacious. [1] [2] [3] There has been growing interest in the optimal duration of index (initial) treatment trial length in attempts to identify people who are more likely to respond to therapy and those who are not. Clinical opinion, expert treatment guidelines, as well as results from RCTs with ADs in MDD have suggested that a minimum duration of 4 to 6 weeks is required to adequately determine the success or failure of an AD index treatment. 4, 5 Replicated studies have provided the impetus for reevaluating the assumption that a minimum of 4 to 6 weeks is required before an AD trial is deemed inefficacious. 1, 2, 6, 7 Emerging evidence indicates that early symptomatic improvement (for example, within the first 2 weeks) identifies a subpopulation of people who will ultimately respond to index therapy. 7, 8 Early symptomatic improvement while on AD therapy has been postulated to be a function of baseline depression severity (that is, greater baseline pretreatment depression severity is more likely to be associated with early symptomatic improvement, compared with placebo). 9 However, a recent meta-analysis conducted by Fournier et al 10 indicated that while people with more severe initial depression may experience a larger magnitude of change at end point (that is, 6 to 8 weeks), there was no clear evidence that baseline severity could be used as a predictor for time to response. The absence of any consistent and reliable predictors of response prior to treatment initiation remains a major deficiency in the treatment of MDD. 11 The observation that early partial symptomatic improvement (for example, 20% or more decrease from baseline in the total HRSD-7 score) identifies a subpopulation that may eventually respond to therapy has significant clinical implications. 1 For example, early symptomatic improvement may inform clinicians about whether or not remaining on an index treatment is likely to be more beneficial than other treatment strategies. Moreover, symptomatic change early in the treatment course would inform ethical considerations and decisions during placebo-controlled trials by indicating whether index therapy should continue unmodified or whether treatment optimization, augmentation, and (or) switching would be required.
Methods
Herein we conducted a nonsystematic review of the extant literature, using Scopus, Google Scholar, and a MeSH key word search, investigating the clinically relevant question: What is the nature and predictive power of early symptomatic improvement with AD therapy? We also review methodological aspects pertinent to the interpretation of time to onset of action. The overarching aim is to provide practitioners with empirically based recommendations pertaining to the optimal duration of index AD therapy before a clinical intervention is warranted.
Conclusions : Les résultats de la réponse pour le TDM sont hétérogènes. Les données disponibles suggèrent que les personnes peuvent répondre tôt, tard, et (ou) continuellement avec le temps, et peuvent représenter des sous-populations distinctes qui fournissent une indication directe des résultats de la réponse au traitement. Néanmoins, une recommandation pratique serait d'envisager une intervention de traitement (par exemple, une optimisation et [ou] augmentation du dosage) si, après 3 à 4 semaines, l'amélioration symptomatique est insuffisante.
Delayed Onset of Action Hypothesis
Quitkin et al 4, 5 evaluated the specificity of AD treatment in people (n = 216) pooled from 3 RCTs. The authors compared 4 active treatments, including 2 tricyclic ADs, imipramine and desipramine; a monoamine oxidase inhibitor, phenelzine; and a tetracyclic, mianserin, to placebo intervention. 4, 5 Unlike previous trials, which relied in large part on a unidimensional end point, this study 4, 5 mapped patterns of either delayed or persistent clinical improvement for each study participant. The primary efficacy parameters in this analysis were the change from baseline to end point on the CGI-I scale (a weekly overall rating of mood change from baseline) and the HRSD-21. The CGI-I and HRSD-21 scores were evaluated at each observation point, and the outcomes were used to develop a pattern for each subject. The investigators reported that a significant percentage of people (27%, 25/92) who had exhibited no symptomatic change by week 4 of treatment subsequently responded when the index trial was extended by 2 weeks. 5 This seminal study 5 formed the empirical basis for recommending a minimum AD trial length of 4 to 6 weeks.
Differential Time to Response With ADs: The Trigger Hypothesis
However, during the last decade, several lines of evidence have accumulated in support of an early response to AD therapy. [12] [13] [14] [15] [16] [17] Stassen et al 13 examined the time characteristics of recovery in a study of 2848 subjects diagnosed with MDD who were treated with 1 of 7 different ADs (that is, imipramine, moclobemide, amitriptyline, fluoxetine, oxaprotiline, mirtazapine, and paroxetine) or placebo. The authors defined improvement (response to therapy) as a 20% or more and a 50% or more reduction from baseline to end point in the total HRSD-17 score, respectively. Results demonstrated that people responded along a continuous distribution of time spans to onset of improvement on all AD medications (including placebo), and all improvement criteria. Each person included was observed to pursue a unique trajectory to onset of improvement (for example, early, compared with late, symptomatic improvement). The mean time to onset of improvement was 13 days (SD 1) and to response was 19 days (SD 1). 13 In contrast with the delayed onset of action hypothesis, the continuous distribution of time to improvement yielded no indication of a distinct drug effect after 3 to 4 weeks into treatment. Specifically, the onset variance among active compounds, and between active and placebo intervention, was marginal. The results of this study 13 provided the basis for the investigators' conclusion that effective ADs trigger and maintain conditions necessary for recovery from depression. Once triggered, recovery appeared to follow a similar pattern across mechanistically dissimilar ADs. This study succeeded in providing evidence against the delayed onset hypothesis; however, the authors did not explicitly discuss potentially effective markers to identify early improvement in MDD.
A separate study addressed this limitation as well as fundamental questions pertaining to the mechanistic basis of Stassen et al's "trigger hypothesis." 13, p 1195 Harmer et al 15 examined the effect of acute AD administration on negative affective bias in depressed patients. The study's premise was based on cognitive psychological models of depression, which demonstrated that depressed patients are more likely to recall negative, rather than positive, emotionally valenced information, and exhibit atypical responses to social cues (for example, facial expressions are interpreted as either more negative, or less positive, than equivalently matched healthy control subjects).
In this RCT (n = 64), 15 the investigators evaluated the effect of a single 4 mg dosage of reboxetine, a noradrenergic reuptake inhibitor, on emotional processing. Participants were given emotional processing tasks as well as preand posttest ratings of mood and anxiety. Adverse events were also obtained. Results of this study 15 indicated that administration of a single 4 mg dosage of reboxetine led to modification of emotional processing after 3 hours of administration in favour of reboxetine, compared with placebo. However, administration of the drug had no effect on measured mood or anxiety symptoms. Under placebo conditions, the depressed patients showed reduced recognition of positive facial expressions, decreased speed in response to positive personality adjectives, and reduced memory for positive information, compared with healthy control subjects. 15 The aforementioned study may provide preliminary insight as to the putative mechanism underlying the observations of Stassen et al. 13 In their study, Harmer et al 15 suggested that there is an inherent delay between the effects of ADs on emotional processing and their subsequent effects on mood. According to this view, effects of ADs on affective bias are immediate, but the translation of these changes into improved mood takes time as the person learns to respond to this unfamiliar positive emotional perspective. It is plausible that the positive emotional perspective may lead to a tendency to interpret social cues as more positive and encourage increased socialization, which may subsequently improve mood and other associated symptoms of depression over time. 15 Additionally, the early effect of AD administration on emotional processing may provide a basis for designing clinical metrics with greater predictive value and improved screening protocols. For example, if acute effects in emotional processing measures are seen reliably with effective ADs in depressed patients within hours of exposure, it may then be possible to use these measures to predict eventual response in depressed patients initiating treatment. In keeping with this view, a similar study demonstrated that an increased recognition of happy facial expressions after 2 weeks of treatment with citalopram in depressed patients predicted eventual therapeutic response after 6 weeks of continued treatment. 16 Taken together, these findings highlight a critical role for the potential early Predicting Treatment Response in Major Depressive Disorder: The Impact of Early Symptomatic Improvement changes that emotional processing may have on predicting future response.
In addition to inducing early cognitive changes, administration of ADs has been shown to affect behaviours that are predictive of future response. Katz et al 12 evaluated early behavioural effects of different ADs, compared with placebo, focusing on the time course of clinical action and the type of behavioural changes that precede recovery in treatment-responsive patients. This was a 6-week RCT comparing paroxetine and desipramine to placebo. As in the Harmer et al study, 15 results from this investigation supported the assertion that ADs can induce a detectable early improvement in patients suffering from MDD. In this study, 12 the onset of clinical action (as measured by improvement in specific behavioural aspects of depression) for desipramine ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16 to 42 days for placebo. After 1 week of treatment, patients given desiparimine showed decreased motor retardation symptoms and an improvement in depressed mood; however, paroxetine initially reduced symptoms of anxiety, followed by improvements in mood and cognition 2 weeks after treatment exposure. In contrast with the AD-responders, patients who responded to placebo showed no consistent or distinctive pattern of behavioural improvement. Each of these early drug-specific behavioural changes were highly predictive of the ultimate clinical response (as defined by 50% or more reduction in HRSD-21) to the different ADs. 15 and Katz et al 12 highlight the importance of developing accurate and senstive metrics for monitoring patient progress. A change from baseline to end point on the total score of an itemized depression metric (for example, HRSD) has conventionally been the standard measure for symptomatic improvement. Harmer et al 15 and Katz et al 12 elected to employ scales that were shown to have greater item sensitivity to AD activity on multiple cognitive and behavioural components. This allowed investigators to detect unique and predictive changes much earlier than previously thought.
Results of both Harmer et al
Moreover, additional evidence suggests that early improvements in neurocognitive performance and (or) biomarkers (for example, neurotrophins or electroencephalographic changes) may be used as an objective measure of progress for AD therapy.
Variability in Study Outcomes: The Contribution of Methodological Heterogeneity
In addition to concerns relating to definitive characteristics for improvement on AD therapy, differential cognitive and (or) behavioural signs of improvement during the course of AD therapy must also be considered. Clinical decisions are frequently dichotomized by standard measures for symptomatic improvement, by monitoring change from baseline to end point on the total score of an itemized depression metric (for example, HRSD); however, response to therapy may also be conceptualized along a continuum. 18, 19 For example, although classified as one disorder, MDD likely has many distinct pathoetiologies, each influencing a patient's treatment trajectory. 19 Hence detection of response will vary depending on which statistical method is employed.
Uher et al 19 recently used a novel method to detect 9 separate trajectories of response to AD therapy. Traditionally, clinical trials have dichotomized continuous measures by creating cut-off scores (for example, HRSD). These category-based, single end point analyses may confound the interpretation of response outcomes owing to their inherent dichotomization. For example, the sensitivity for single-point analysis accounts for factors beyond those of AD therapy. Moreover, single-point analysis limits the ability of investigators to monitor individual temporal patterns of change.
Gueorguieva et al 20 conducted a recent study seeking to characterize heterogeneity in time to clinical response (n = 2515). Investigators reexamined clinical trials of duloxetine, fluoxetine, paroxetine, and escitalopram, compared with placebo, and employed statistical methods (that is, growth mixture modelling 21 ) designed to capture response heterogeneity by measuring distinct trajectories of HRSD-17 scores during treatment. This is in contrast to conventional end point and mixed-model statistical analyses that have been performed in previous studies. Overall, investigators confirmed early signs of improvement within 2 weeks of therapy, identifying 76.3% of the sample to be exhibiting a response trajectory and 23.7% exhibiting a nonresponse trajectory. Interestingly, this analysis revealed that some subjects treated with ADs exhibited symptom worsening, compared with those receiving placebo. Given that clinical trials focus on the average treatment response and end point analysis, investigators postulated that these results may have falsely led to conclusions that one must stay on ADs for 4 to 6 weeks before improvement is seen. Investigators also suggested that novel strategies be implemented, such as trajectory analysis or subpopulation analysis, to account for sample heterogeneity to better detect treatment effectiveness.
What Is the Optimal Trial Duration With ADs?
Despite extensive research refuting the delayed onset hypothesis, alternative treatment durations for AD trials have not been described for people on AD therapy in the absence of clinically significant partial improvement. 1, 7, 8, [21] [22] [23] [24] [25] [26] If a treatment trial is prematurely discontinued, the risk of ending a potentially efficacious treatment is increased. This undesirable outcome needs to be balanced with the equally undesirable outcome of unnecessarily extending a treatment intervention that is not expected to result in remission. The latter scenario is commonly encountered in clinical practice, contributing to morbidity, negative attitudes toward treatment, noncompliance, and increased exposure to the hazards of MDD (for example, suicidality).
In 1996, Quitkin et al 27 culled data from a 10-year period as part of an effort to revisit the notion of time to response with AD therapy, in follow-up to their 1984 study. 4 This study evaluated the likelihood of response at week 6 for subjects (n = 382) who were unimproved at each week prior. Response was tracked using a 7-point CGI-I. All subjects who received a score from 4 to 7 were considered to be nonresponders. The study consisted of 5 drug-placebo comparisons and 3 drug-drug comparisons, including 3 monoamine oxidase inhibitors (that is, phenelzine, tranylcypromine, deprenyl), 3 tricyclic ADs (that is, imipramine, desipramine, amitriptyline), and a tetracyclic AD (that is, mianserin). For nonresponders at weeks 1, 2, 3, 4, and 5, the likelihood of converting to a positive response at week 6 was 52%, 44%, 32%, 13%, and 3%, respectively. Investigators arbitrarily selected 13% as a cut-off point and recommended that a trial of ADs be discontinued if no signs of improvement are seen within 4 weeks, contrary to their initial study in 1984. 4, 27 Response rates in subjects who initially show minimal symptomatic improvement with AD therapy continue to be investigated to guide optimal trial length; however, results of these studies have yielded inconsistent results. [2] [3] [4] 11, 27, 28 Depending on the methodology and the study window used, conversion rate studies have suggested an index treatment duration of anywhere from 4 to 8 weeks before a clinical intervention is warranted. 2, 11, 28 Given the highly variable results, another tool to predict future response is necessary.
To address this, numerous trials have examined the use of the PPV and the NPV to help decide on the optimal trial length ( Table 1) . 1, 7, 21, 25, 26, 29 Szegedi et al 1 published a large meta-analysis evaluating whether early improvement (that is, 20% or more reduction from baseline on HRSD-17) with AD therapy in the first 2 weeks predicts treatment outcomes in patients with MDD. Investigators included 41 clinical trials, comparing mirtazapine with active comparators or placebo in a sample of 6562 in-and outpatients. Results of this analysis indicated that early improvement predicted stable response (that is, reduction in HRSD-17 score of 50% or more from baseline at 4 weeks of treatment and all subsequent assessments) and stable remission (that is, reduction in HRSD-17 score to 6 points or less at week 4 of treatment and all subsequent assessments) with high sensitivity. NPVs for stable responders and stable remitters were much higher across various treatment modalities, in the range of 82% to 100%, compared with 19% to 60% PPVs. 1 Given these results, investigators concluded that early improvement within 2 weeks with AD therapy can predict treatment outcomes with high sensitivity. Moreover, the lack of early symptomatic improvement has a high NPV, which indicates its clinical utility in identifying people who should no longer continue index treatment.
Concerns regarding the adequate duration for effective AD trials continue to emerge as discrepant results from conversion rate studies, as well as studies evaluating the clinical utility of NPV and PPV, challenge what constitutes an effective AD trial. Conversion rate studies have largely indicated that a substantial minority of subjects respond to continued AD therapy, even in the absence of many weeks of improvement. 30 This has provided clinicians with some justification for extending AD trials beyond the traditional 4 to 6 weeks. However, given the evidence, both against and in support of the delayed onset hypothesis, and other studies underscoring the robust NPV of the lack of early improvement, extending a trial beyond 4 to 6 weeks may be ill-advised if measurement-based care reveals no improvement in severity scores. For example, in clinical practice, it would be unlikely that many patients would be willing to pursue treatment trials beyond 6 weeks of treatment in the absence of any subjectively noted and (or) objectively confirmed symptomatic benefit. Relatively few studies have empirically evaluated whether pursuing treatment with an insufficient AD after 4 weeks, compared with switching to an alternative treatment, would offer differential response outcomes.
One study, completed by Romera et al, 31 sought to compare early and delayed switch to duloxetine in MDD subjects who did not experience improvement after 4 weeks of escitalopram treatment. Results of this study indicated that those subjects randomized to the early switch strategy (switched at 4, compared with 8, weeks) achieved greater confirmed remission (that is, HRSD-17 score of less than 7) when compared to the delayed switch arm. Investigators concluded that continuation of an index AD offers inferior Predicting Treatment Response in Major Depressive Disorder: The Impact of Early Symptomatic Improvement remission rates to switching to a mechanistically dissimilar approach if the index trial is insufficient after 4 weeks.
Results of this study 31 may be used to suggest that patients who do not improve may benefit from a treatment switch that occurs earlier than usual; notwithstanding, other studies have failed to confirm this finding. 32, 33 Further, it remains unclear whether the improvement observed resulted from a switch from an SSRI to a serotonin and norepinephrine reuptake inhibitor, or if switching to an alternative medication of the same class (for example, SSRIs) would have yielded similar benefits.
Conclusion
Taken together, the preponderance of contemporary studies suggests that a subpopulation of people who exhibit early partial symptomatic improvement have an increased likelihood of eventually responding to therapy. Conversely, the lack of early, partial symptomatic improvement identifies a subpopulation with decreased likelihood of eventual improvement. It appears that effective ADs trigger and maintain immediate changes (within hours to days of first dose) in cognition and emotional processing, even if subjective changes in mood or anxiety symptoms are not yet apparent. These changes in emotional processing then affect specific behavioural components of MDD within weeks. Following these changes, recovery from MDD may be achieved. In the absence of any empirically established baseline predictors of AD response, early partial symptomatic improvement emerges as a robust indicator of outcome with a chosen treatment modality.
There are several methodological limitations that affect interpretation of the available data. We have suggested that heterogeneity in statistical methods is a fundamental source of variation between study results. Moreover, sample compositions have been inconsistent, including people with varying degrees of baseline depression severity. This latter observation is critical as replicated evidence indicates that statistically significant differences between ADs and placebo are less likely to be observed after 6 to 8 weeks of treatment in people with milder severity scores. 10 Further, it should not be assumed that the response trajectories would be identical between ADs and other modalities of intervention (for example, neuromodulation and psychotherapy).
Notwithstanding, measurement-based clinical practice should be the standard of care as part of chronic disease management. Many studies have used the HRSD-17 to monitor patient progress in clinical trials; however, the use of such scales in a clinical environment is impractical. As an alternative, abbreviated metrics, such as the Patient Health Questionnaire-9 or the HRSD-7, have been validated, and can be used to equivalently measure partial symptomatic improvement as defined by a 20% or more reduction from baseline depression severity 34 (Figure 1 ). People not exhibiting partial symptomatic improvement after 3 to 4 weeks should be considered for intervention. Admittedly, this recommendation is largely based on pragmatism, as early improvement is probabilistic rather than deterministic of eventual remission. Moreover, available evidence indicates that there is a subpopulation of people who will eventually improve with treatment, despite 4 to 6 weeks Assess depression severity with MBC to determine if early clinically significant symptomatic improvement has occurred that is 20% or more reduction in depression
Week 0
Week 2 symptomatic improvement has occurred, that is, 20% or more reduction in depression severity. No further intervention required.
Assess depression severity with MBC to determine if early clinically significant symptomatic improvement has occurred. Determine if further intervention is warranted.
Week 3-4 symptomatic improvement has occurred. Determine if further intervention is warranted.
Treatment strategy
Consider optimization of treatment If 19% or less reduction in severity as measured by MBC If 20% or more reduction in severity as measured by MBC Consider optimization of treatment (for example, dosage optimization, adjunctive medication or manualbased psychotherapy (for example, cognitive-behavioural therapy)
Continue with index AD and dosage. Periodic assessment on a regular basis.
of ineffective therapy. 21 Ultimately, however, we conclude that the continuation of AD treatment in the absence of symptomatic improvement beyond 3 to 4 weeks is difficult to justify.
